The Roswell Park Cancer Institute (RPCI) has been continuously recognized as a Comprehensive Cancer Center since the NCI designation of such centers in 1974 and is now requesting continued federal support for the next five years. A free-standing research, education and clinical cancer care Institute, RPCI occupies a 27 acre campus near downtown Buffalo and has expanded to nearly 1.6M gsf of clinical and research space, a 16% increase since the last review period. RPCI serves a population base of ~1.5M in Western New York where the RPCI tumor registry is recording more than 3,400 new cancer patients per year. RPCI has strong collaborations with the University of Buffalo and the Hauptman-Woodward Institute for Structural Biology, but is a fully independent entity with Dr. Donald Trump, CCSG PI and RPCI President/CEO, answering only to the RPCI Board of Directors. Since the last competitive renewal, the RPCI has grown significantly as demonstrated by: 1) the recruitment of over 100 new faculty clinicians and researchers of which 43 are new CCSG members;2) a 74% increase in total NCI funding and a 44% increase in total peer-reviewed funding;3) a 73% increase in accrual to investigator-initiated, interventional clinical trials and a 44% increase to accrual in all interventional trials;4) the addition of 4 new shared resources with an institutional investment of over $2.0 M and (5) the opening of a new, 177,000 gsf, state-of-the-art research building housing Program member laboratories and Shared Resources. With the growth in faculty has also come the recruitment of three Senior Leaders. In addition, a director for the newly created RPCI Office of Cancer Health Disparities Research has also been recruited. As part of the scientific growth within RPCI, a new disease-specific Research Program, the Prostate Program, has been added in this renewal bringing RPCI to a total of six Scientific Programs that also include Cancer Prevention &Population Sciences, Cell Stress &Biophysical Therapies, Genetics, Molecular Targets &Experimental Therapeutics and Tumor Immunology &Immunotherapy. With strong leadership and institutional commitment, RPCI will continue to focus on recruiting talented investigators to further expand research efforts targeting areas in genetics, investigational imaging and cancer health disparities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016056-34S2
Application #
8118319
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1997-06-16
Project End
2013-04-30
Budget Start
2010-05-18
Budget End
2011-04-30
Support Year
34
Fiscal Year
2010
Total Cost
$100,000
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Burkard-Mandel, Lauren; O'Neill, Rachel; Colligan, Sean et al. (2018) Tumor-derived thymic stromal lymphopoietin enhances lung metastasis through an alveolar macrophage-dependent mechanism. Oncoimmunology 7:e1419115
Rosario, S R; Long, M D; Affronti, H C et al. (2018) Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas. Nat Commun 9:5330
Wang, Xue; Niu, Jin; Li, Jun et al. (2018) Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar). Mol Cell Proteomics 17:655-671
Narayanan, Sumana; Kawaguchi, Tsutomu; Yan, Li et al. (2018) Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer. Ann Surg Oncol 25:2323-2331
Ratajczak, Alexsandra; Feleszko, Wojciech; Smith, Danielle M et al. (2018) How close are we to definitively identifying the respiratory health effects of e-cigarettes? Expert Rev Respir Med 12:549-556
Tsuji, Takemasa; Yoneda, Akira; Matsuzaki, Junko et al. (2018) Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy. Cancer Immunol Res 6:594-604
Zhu, Qianqian; Yan, Li; Liu, Qian et al. (2018) Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. Blood 131:2490-2499
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Terakawa, Tomoaki; Katsuta, Eriko; Yan, Li et al. (2018) High expression of SLCO2B1 is associated with prostate cancer recurrence after radical prostatectomy. Oncotarget 9:14207-14218
Mastri, Michalis; Lee, Christina R; Tracz, Amanda et al. (2018) Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors. Mol Cancer Ther 17:1602-1612

Showing the most recent 10 out of 1555 publications